DK3070174T3 - Opsporing af lægemidler på grundlag af in vitro-differentierede celler - Google Patents

Opsporing af lægemidler på grundlag af in vitro-differentierede celler Download PDF

Info

Publication number
DK3070174T3
DK3070174T3 DK16165848.9T DK16165848T DK3070174T3 DK 3070174 T3 DK3070174 T3 DK 3070174T3 DK 16165848 T DK16165848 T DK 16165848T DK 3070174 T3 DK3070174 T3 DK 3070174T3
Authority
DK
Denmark
Prior art keywords
determination
differentiated cells
vitro differentiated
medicines based
vitro
Prior art date
Application number
DK16165848.9T
Other languages
English (en)
Inventor
Heribert Bohlen
Kristina Tressat
Silke Schwengberg
Andreas Ehlich
Original Assignee
Ncardia Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34924969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3070174(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ncardia Ag filed Critical Ncardia Ag
Application granted granted Critical
Publication of DK3070174T3 publication Critical patent/DK3070174T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
DK16165848.9T 2004-05-11 2005-05-11 Opsporing af lægemidler på grundlag af in vitro-differentierede celler DK3070174T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04011214 2004-05-11
EP10010425.6A EP2270196B1 (en) 2004-05-11 2005-05-11 Assay for drug discovery based on in vitro differentiated cells

Publications (1)

Publication Number Publication Date
DK3070174T3 true DK3070174T3 (da) 2020-01-27

Family

ID=34924969

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05740642.3T DK1745144T3 (da) 2004-05-11 2005-05-11 Analysefremgangsmåde til opsporing af lægemidler på grundlag af in vitro-differentierede celler
DK16165848.9T DK3070174T3 (da) 2004-05-11 2005-05-11 Opsporing af lægemidler på grundlag af in vitro-differentierede celler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05740642.3T DK1745144T3 (da) 2004-05-11 2005-05-11 Analysefremgangsmåde til opsporing af lægemidler på grundlag af in vitro-differentierede celler

Country Status (9)

Country Link
US (6) US8318488B1 (da)
EP (3) EP2270196B1 (da)
JP (2) JP4814875B2 (da)
AT (1) ATE490306T1 (da)
CA (1) CA2565858C (da)
DE (1) DE602005025106D1 (da)
DK (2) DK1745144T3 (da)
ES (3) ES2770067T3 (da)
WO (1) WO2005108598A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9945840B2 (en) 2004-04-07 2018-04-17 Axiogenesis Ag Non-invasive, in vitro functional tissue assay systems
ATE490306T1 (de) * 2004-05-11 2010-12-15 Axiogenesis Ag Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen
US8568761B2 (en) * 2005-07-15 2013-10-29 Cormatrix Cardiovascular, Inc. Compositions for regenerating defective or absent myocardium
EP3495822B1 (en) 2006-04-04 2023-12-20 Novilux, LLC Method for assessing acute myocardial infarction based on highly sensitive analysis of cardiac troponin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US20100248229A1 (en) * 2007-04-20 2010-09-30 Stempeutics Research Private Limited Invitro human embryonic model and a method thereof
JP5734869B2 (ja) * 2008-12-16 2015-06-17 オンコノバ・セラピューティックス・インコーポレーテッド ヒトにおける細胞毒性物質の有害作用に対する治療レジメンの有効性を決定する方法
US10386360B2 (en) 2009-03-13 2019-08-20 University Of Central Florida Research Foundation, Inc. Bio-microelectromechanical system transducer and associated methods
US8815584B1 (en) 2009-04-23 2014-08-26 University Of Central Florida Research Foundation, Inc. Method of co-culturing mammalian muscle cells and motoneurons
US9163216B1 (en) 2009-04-23 2015-10-20 University Of Central Florida Research Foundation, Inc. Method for culturing skeletal muscle for tissue engineering
US8385624B2 (en) 2009-05-13 2013-02-26 David J. Charlot Automated transient image cytometry
US8828721B1 (en) 2009-05-28 2014-09-09 University Of Central Florida Research Foundation, Inc. Method of myelinating isolated motoneurons
JP5678045B2 (ja) 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
JP6083559B2 (ja) * 2009-07-31 2017-02-22 クロモセル コーポレーション 細胞運命の修飾因子を同定および検証するための方法および組成物
DE102009041254A1 (de) * 2009-09-11 2011-06-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 80686 Spontan kontrahierende Fischzellaggregate, deren Verwendung und Verfahren zu deren Erzeugung
US9404140B1 (en) * 2009-11-03 2016-08-02 The University Of Central Florida Research Foundation, Inc. Patterned cardiomyocyte culture on microelectrode array
EP2531910B1 (en) 2010-02-05 2015-04-08 University of Central Florida Research Foundation, Inc. Methods for identifying points of action in electrically active cells
US8615311B2 (en) * 2010-03-15 2013-12-24 Rutgers, The State University Of New Jersey Microelectorode array, methods for preparing the same and uses thereof
EP2585171B1 (en) 2010-04-23 2018-12-26 University Of Central Florida Research Foundation, Inc. Formation of neuromuscular junctions in a defined system
WO2012002460A1 (ja) 2010-06-29 2012-01-05 公立大学法人名古屋市立大学 イオンチャネルに作用する化合物のスクリーニング用材料及びその利用
US20130109048A1 (en) * 2010-07-09 2013-05-02 Ecole Polytechnique Federale De Lausanne (Epfl) Method for in-vitro monitoring of neuronal disorders and use thereof
EP2633322B1 (en) * 2010-10-29 2018-02-14 F. Hoffmann-La Roche AG Method of determining risk of arrythmia
WO2012098260A1 (en) 2011-01-21 2012-07-26 Axiogenesis Ag A non-viral system for the generation of induced pluripotent stem (ips) cells
JP5995086B2 (ja) * 2011-02-07 2016-09-21 国立大学法人京都大学 心筋症特異的多能性幹細胞およびその用途
WO2013013206A1 (en) 2011-07-21 2013-01-24 The Board Of Trustees Of The Leland Stanford Junior University Cardiomyocytes from induced pluripotent stem cells from patients and methods of use
JP2015524674A (ja) * 2012-08-17 2015-08-27 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 哺乳動物系の機能的なインビトロ細胞モデルについての方法、システム、および組成物
US9939372B2 (en) 2012-12-14 2018-04-10 Vala Science, Inc. Analysis of action potentials, transients, and ion flux in excitable cells
CA2899445C (en) 2013-01-30 2023-04-04 University Of Central Florida Research Foundation, Inc. Devices and systems for mimicking heart function
CN104237308B (zh) * 2013-06-09 2016-08-31 国家纳米科学中心 一种在体外筛选药物的方法
DE102013114671B4 (de) * 2013-12-20 2015-10-29 Universität Rostock Verfahren zur Erzeugung von Sinusknotenzellen ("Herz-Schrittmacherzellen") aus Stammzellen
WO2015150589A1 (en) * 2014-04-03 2015-10-08 Imec Vzw Method and device for drug screening
US10935541B2 (en) 2014-08-07 2021-03-02 University Of Central Florida Research Foundation, Inc. Devices and methods comprising neuromuscular junctions
WO2018144770A1 (en) * 2017-02-04 2018-08-09 AnaBios Corporation System and methods for predicting drug-induced inotropic and pro-arrhythmia risk
US11474103B2 (en) * 2017-02-17 2022-10-18 Koniku Inc. Systems for detection
NL2019618B1 (en) 2017-09-22 2019-03-28 Ncardia B V In vitro method for providing stem cell derived cardiomyocytes
US20190376039A1 (en) * 2018-06-08 2019-12-12 L. Lee Lochbaum Eckhardt Cells with improved inward rectifier current
WO2020066396A1 (ja) * 2018-09-28 2020-04-02 日本ゼオン株式会社 心毒性評価方法
CN110161111B (zh) * 2019-04-15 2021-09-07 广东工业大学 一种检测动物组织中β肾上腺素受体激动剂类药物的方法
JP7543656B2 (ja) * 2020-02-19 2024-09-03 日本ゼオン株式会社 心毒性評価方法
WO2022266431A1 (en) * 2021-06-18 2022-12-22 The Texas A&M University System Methods of processing adult neural cells from mammals and assays thereof
US12076437B2 (en) 2021-07-12 2024-09-03 Brown University Proangiogenic protein cocktails delivered in custom biomaterials to revascularize ischemic tissue
CN118139973A (zh) * 2021-10-20 2024-06-04 艾克希尔股份有限公司 用于使用非人灵长类动物的个体化的基因组组装和诱导性多能干细胞系进行临床前评估的组合物和方法
WO2024162286A1 (ja) * 2023-01-31 2024-08-08 富士フイルム株式会社 薬剤の評価方法、試薬およびキット

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6072402A (en) 1992-01-09 2000-06-06 Slc Technologies, Inc. Secure entry system with radio communications
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
US4931561A (en) 1987-07-29 1990-06-05 Koei Chemical Co., Ltd. Process for preparing nitriles
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
JP3127158B2 (ja) 1989-10-05 2001-01-22 オプテイン，インコーポレイティド 新規の遺伝子及びポリペチドの無細胞合成並びに単離
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
DD299439B5 (de) 1990-05-11 1995-10-19 Inst Pflanzengenetik & Kultur Verfahren zur Untersuchung der Wirkung von chemischen Wirkstoffen und medizinisch-pharmazeutischen Praeparaten
JPH07501206A (ja) 1991-08-07 1995-02-09 イェシバ・ユニバーシティ 前駆肝細胞の増殖
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
DE69435112D1 (de) 1993-09-10 2008-08-21 Univ Columbia Verwendung von grünem fluoreszenzprotein
US6015671A (en) 1995-06-07 2000-01-18 Indiana University Foundation Myocardial grafts and cellular compositions
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US5534404A (en) 1993-12-10 1996-07-09 Cytotherapeutics, Inc. Glucose responsive insulin secreting β-cell lines and method for producing same
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5563067A (en) 1994-06-13 1996-10-08 Matsushita Electric Industrial Co., Ltd. Cell potential measurement apparatus having a plurality of microelectrodes
DE4441327C1 (de) 1994-11-22 1995-11-09 Inst Pflanzengenetik & Kultur Embryonale Herzmuskelzellen, ihre Herstellung und ihre Verwendung
US5641644A (en) 1994-12-09 1997-06-24 Board Of Regents, The University Of Texas System Method and apparatus for the precise positioning of cells
US5565340A (en) 1995-01-27 1996-10-15 Clontech Laboratories, Inc. Method for suppressing DNA fragment amplification during PCR
US6110743A (en) 1995-02-10 2000-08-29 The Regents Of The University Of California Development and use of human pancreatic cell lines
GB9504446D0 (en) 1995-03-06 1995-04-26 Medical Res Council Improvements in or relating to gene expression
GB9505663D0 (en) 1995-03-21 1995-05-10 Stringer Bradley M J Genetically modified neural cells
DE19525285C2 (de) 1995-06-28 1999-04-15 Inst Pflanzengenetik & Kultur In vitro Testverfahren zum Nachweis Chemikalien-induzierter embryotoxischer/teratogener Effekte
DE19529371C3 (de) 1995-08-10 2003-05-28 Nmi Univ Tuebingen Mikroelektroden-Anordnung
US6166288A (en) 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
WO1997025412A1 (en) 1996-01-09 1997-07-17 The Regents Of The University Of California Ungulate embryonic stem-like cells, methods of making and using the cells to produce transgenic ungulates
US5869243A (en) 1996-03-05 1999-02-09 Rhode Island Hospital Immortalized hepatocytes
US6333447B1 (en) 1996-03-29 2001-12-25 The General Hospital Corporation Transgenic model of heart failure
EP2213740A1 (en) 1996-10-01 2010-08-04 The Regents of the University of Colorado Human telomerase catalytic subunit
WO1998022819A1 (de) 1996-11-16 1998-05-28 Nmi Naturwissenschaftliches Und Medizinisches Institut An Der Universität Tübingen In Reutlingen Stiftung Bürgerlichen Rechts Mikroelementenanordnung, verfahren zum kontaktieren von in einer flüssigen umgebung befindlichen zellen und verfahren zum herstellen einer mikroelementenanordnung
DE19653685B4 (de) 1996-12-13 2006-06-01 Institut für Pflanzengenetik und Kulturpflanzenforschung In vitro Zellsystem vaskulärer glatter Muskulatur für pharmakologische und physiologische Untersuchungen
CA2281648A1 (en) 1997-02-13 1998-08-20 Memorial Sloan-Kettering Cancer Center Hybrid molecules for optically detecting changes in cellular microenvironments
JPH10292688A (ja) 1997-02-20 1998-11-04 Kouji Kagetani 扉の施解錠方法
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
DE19815128A1 (de) 1997-04-03 1998-10-08 Franz Wolfgang M Dr Transgenes Tiermodell für humane Kardiomyopathien
US6218597B1 (en) 1997-04-03 2001-04-17 University Technology Corporation Transgenic model and treatment for heart disease
GB9708526D0 (en) 1997-04-25 1997-06-18 Royal Free Hosp School Med Eukaryotic gene expression cassette and uses thereof
US5981268A (en) 1997-05-30 1999-11-09 Board Of Trustees, Leland Stanford, Jr. University Hybrid biosensors
DE19727962A1 (de) 1997-07-02 1999-01-14 Juergen Hescheler Fluoreszierende Proteine als zelltypspezifische Reporter
JP2001514883A (ja) 1997-08-12 2001-09-18 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトｆｒｉｚｚｌｅｄ様タンパク質
JP2001520170A (ja) * 1997-10-16 2001-10-30 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｎｆ−ａｔ３機能に関連した心肥大動物モデルと治療法
US6610480B1 (en) 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
WO1999027113A1 (en) 1997-11-26 1999-06-03 Geron Corporation Mouse telomerase reverse transcriptase
US6080576A (en) 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
DE19843234A1 (de) 1998-09-09 2000-03-23 Inst Pflanzengenetik & Kultur Differenzierte Herzzellen mit pathologischen Merkmalen als in vitro-Modell für Herzerkrankungen
WO2000017326A1 (en) 1998-09-21 2000-03-30 Musc Foundation For Research Development Non-hematopoietic cells, including cardiomyocytes and skeletal muscle cells, derived from hematopoietic stem cells and methods of making and using them
GB2342003A (en) 1998-09-21 2000-03-29 Riva Limited Telephone apparatus for handling anonymous calls
CA2346459A1 (en) 1998-10-07 2000-04-13 The Board Of Trustees Of The University Of Arkansas In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
AU778844B2 (en) 1998-12-09 2004-12-23 Vistagen, Inc. Toxicity typing using embryoid bodies
GB2344670B (en) 1998-12-12 2003-09-03 Ibm System, apparatus and method for controlling access
US6377057B1 (en) 1999-02-18 2002-04-23 The Board Of Trustees Of The Leland Stanford Junior University Classification of biological agents according to the spectral density signature of evoked changes in cellular electric potential
WO2000063221A2 (en) 1999-04-21 2000-10-26 Human Genome Sciences, Inc. Galectin 11
EP1192281A2 (en) 1999-07-07 2002-04-03 Regeneron Pharmaceuticals, Inc. Use of ras inhibitors for inhibiting muscle atrophy
EP1210453B1 (en) * 1999-08-20 2009-02-11 Board Of Regents, The University Of Texas System Hdac4 and hdac5 in the regulation of cardiac gene expression
US20030059797A1 (en) 1999-08-27 2003-03-27 Elena Paley Animal model of and test for Alzheimer's disease
WO2001023555A1 (fr) 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Prolongation de la duree de vie d'une cellule normale
EP1107003A1 (en) 1999-12-09 2001-06-13 Trophos Methods for screening compounds active on neurons
DE19962154A1 (de) 1999-12-22 2001-07-12 Medigene Ag Krankhaft veränderte Herzmuskelzelle, ihre Herstellung und Verwendung
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
EP1309856A2 (de) 2000-03-01 2003-05-14 Nmi Naturwissenschaftliches Und Medizinisches Institut An Der Universität Tübingen Verwendung eines elektrodenarrays
CA2402245A1 (en) 2000-03-10 2001-09-20 Advanced Research And Technology Institute, Inc. Multipotent cell and cardiomyocyte cell populations, and routes to and uses of same
AU2001255467A1 (en) 2000-04-19 2001-11-07 Pierre C Van Rysselberghe Security systems for delivering goods and services
US7282366B2 (en) 2000-04-27 2007-10-16 Geron Corporation Hepatocytes for therapy and drug screening made from embryonic stem cells
US7256042B2 (en) * 2000-04-27 2007-08-14 Geron Corporation Process for making hepatocytes from pluripotent stem cells
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
AU2001261650A1 (en) 2000-05-15 2001-11-26 Geron Corporation Ovine tissue for xenotransplantation
IL154159A0 (en) 2000-08-01 2003-07-31 Yissum Res Dev Co Directed differentiation of ebryonic cells
JP2002051782A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd 骨粗鬆症もしくは関節リウマチの治療または予防剤の試験方法
SE520984C2 (sv) 2000-08-10 2003-09-16 Volvo Technology Corp Metod och system för att låsa upp ett föremål
US7214371B1 (en) 2000-09-01 2007-05-08 Ben-Gurion University Of The Negev Research & Development Authority Tissue engineered biografts for repair of damaged myocardium
US6844184B2 (en) 2000-11-08 2005-01-18 Surface Logix, Inc. Device for arraying biomolecules and for monitoring cell motility in real-time
US20030027331A1 (en) 2000-11-30 2003-02-06 Yan Wen Liang Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
GB2386609C2 (en) 2000-12-27 2014-01-08 Axiogenesis Ag System for the cell-specific and development-specific selection of differentiating embryonic stem cells adult stem cells and embryonic germline cells
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AU2002306763A1 (en) * 2001-03-20 2002-10-03 University Of Virginian Patent Foundation Methods for identifying and purifying smooth muscle progenitor cells
US20030148296A1 (en) 2001-03-30 2003-08-07 Brown Harlan Roger Differential gene expression in cardiac hypertrophy
US20030032185A1 (en) 2001-05-03 2003-02-13 Sharkis Saul J. Method of making a homogeneous preparation of hematopoietic stem cells
DE10126371A1 (de) 2001-05-30 2003-02-27 Medigene Ag Verfahren zur Identifizierung von Substanzen gegen Herzmuskelzellen-Hypertrophie
WO2004005882A2 (en) 2001-06-18 2004-01-15 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (mphts)
US20030108895A1 (en) 2001-06-25 2003-06-12 Field Loren J. Methods and cell populations for identifying and validating genomic targets, and for drug screening
EP1271145A1 (en) 2001-06-25 2003-01-02 Cardion AG Methods and cell populations for identifying and validating genomic targets, and for drug screening
CA2351156A1 (en) 2001-07-04 2003-01-04 Peter W. Zandstra A bioprocess for the generation of pluripotent cell derived cells and tissues
GB2393734B (en) 2001-07-12 2005-07-27 Geron Corp Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
EP1421182A4 (en) 2001-07-24 2005-03-23 Es Cell Int Pte Ltd PROCESS FOR INDUCING DIFFERENTIATION OF STEM CELLS
DE60231625D1 (de) 2001-08-14 2009-04-30 Univ St Louis Systeme und verfahren zum screening pharmazeutischer chemikalien
WO2003018760A2 (en) 2001-08-24 2003-03-06 Advanced Cell Technology, Inc. Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
AU2002338732A1 (en) 2001-09-19 2003-04-01 Medigene Ag Extracellular regulated kinase 2 (erk2)
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US20030082153A1 (en) 2001-10-22 2003-05-01 The Government Of The United States Of America Stem cells that transform to beating cardiomyocytes
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US6743962B2 (en) 2002-01-31 2004-06-01 Chevron U.S.A. Inc. Preparation of high octane alkylate from Fischer-Tropsch olefins
CA2385734A1 (en) 2002-03-04 2003-09-04 Board Of Regents, The University Of Texas System Transgenic cardiomyoctes with controlled proliferation and differentiation
US20050201991A1 (en) * 2002-03-19 2005-09-15 Peter Andrews Stem cell culture
GB2387501A (en) 2002-04-11 2003-10-15 Andrew Nicholas Door intercom system with remote screening/access control via a mobile phone
WO2003093501A2 (en) 2002-04-30 2003-11-13 University Of Bremen Ssh based methods for identifying and isolating unique nucleic acid sequences
GB0215044D0 (en) 2002-06-28 2002-08-07 Sciona Ltd Sampling kits, devices and uses thereof
AU2003252155B2 (en) 2002-07-26 2009-01-22 Wisconsin Alumni Research Foundation Functional cardiomyocytes from human embryonic stem cells
US7627535B2 (en) 2002-12-13 2009-12-01 Newspaper Delivery Technologies, Inc. Method and apparatus for supporting delivery, sale and billing of perishable and time-sensitive goods such as newspapers, periodicals and direct marketing and promotional materials
EP3184629A1 (en) 2003-06-20 2017-06-28 Axiogenesis Ag Drug discovery based on in vitro generated tissue
EP1644485B9 (en) 2003-07-08 2012-01-04 Axiogenesis Ag Secreted proteins as markers for cell differentiation
WO2005005621A2 (en) 2003-07-08 2005-01-20 Axiogenesis Ag NOVEL METHOD FOR THE PREPARATION OF EMBRYOID BODIES (EBs) AND USES THEREOF
US7452718B2 (en) 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
US9945840B2 (en) 2004-04-07 2018-04-17 Axiogenesis Ag Non-invasive, in vitro functional tissue assay systems
GB0410011D0 (en) 2004-05-05 2004-06-09 Novartis Forschungsstiftung Neural cell differentiation method
ATE490306T1 (de) * 2004-05-11 2010-12-15 Axiogenesis Ag Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen
WO2007069666A1 (ja) 2005-12-13 2007-06-21 Kyoto University 核初期化因子

Also Published As

Publication number Publication date
US20160209399A1 (en) 2016-07-21
CA2565858A1 (en) 2005-11-17
EP2270196B1 (en) 2016-04-20
US9726662B2 (en) 2017-08-08
JP2007537429A (ja) 2007-12-20
US8318488B1 (en) 2012-11-27
CA2565858C (en) 2021-06-22
EP3070174A1 (en) 2016-09-21
EP1745144B1 (en) 2010-12-01
US20160209398A1 (en) 2016-07-21
US20130102497A1 (en) 2013-04-25
JP4814875B2 (ja) 2011-11-16
ATE490306T1 (de) 2010-12-15
JP2012010701A (ja) 2012-01-19
ES2770067T3 (es) 2020-06-30
ES2579954T3 (es) 2016-08-17
WO2005108598A1 (en) 2005-11-17
DE602005025106D1 (de) 2011-01-13
EP2270196A2 (en) 2011-01-05
EP2270196A3 (en) 2011-03-02
US20230160877A1 (en) 2023-05-25
EP3070174B1 (en) 2019-11-06
ES2354997T3 (es) 2011-03-21
EP1745144A1 (en) 2007-01-24
DK1745144T3 (da) 2011-02-07
US20160209400A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
DK3070174T3 (da) Opsporing af lægemidler på grundlag af in vitro-differentierede celler
DE602005008514D1 (de) Navigationssystem und Verkersprognoseverfahren
ATE513581T1 (de) Portabler applikator zur kollagenstimulation
BRPI0510225A (pt) fixador interno e sistema para detecção do ponto de referência no mencionado fixador
IL185668A0 (en) Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
DK1773796T3 (da) Oxopiperidinderivater, fremstilling deraf samt terapeutisk anvendelse deraf
ATE400319T1 (de) Tetrahydropyridothiophene
DK2076588T3 (da) Ekspansionsfremgangsmåde til voksne stamceller fra blod, især perifert blod, og dermed forbundet anvendelse på det medicinske område
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
ES1060753Y (es) "dispositivo de control y valoracion de acciones deportivas".
EP1766043A4 (en) COMPUTER SYSTEMS AND METHODS FOR CONSTRUCTING BIOLOGICAL CLASSIFIERS AND USES THEREOF
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
WO2006012521A3 (en) Treatment for ocular disease
FR2870539B1 (fr) Nouvelles methodes et medicaments
GB0616939D0 (en) Test for the detection of active enzyme systems in human or animal bodies
TW200612896A (en) Pharmaceutical compositions containing with HMG-CoA reductase inhibitor and glutathione
WO2007111628A3 (en) Mxa as an antiviral drug and as a target for identification of antiviral drugs for dna virus infections
ITBZ20040033A1 (it) Impianto di rilevamento dell'umidita'.
ITMI20051568A1 (it) Biopeptidi ad attivita' antipertensiva derivanti dalla beta-caseina bovina
GB0525877D0 (en) Processor for use in replication of databases and system and method including the processor
FR2876357B1 (fr) Cavalier plat de presentation pour socquettes et analogue
ITMO20040175A1 (it) Dispositivo per l'introduzione ed il posizionamento di stent in vasi sangugni.
UA10045S (uk) Піктограма фармацевтичного засобу (в таблетках)
Park et al. Analysis on the Expectiation of Role Execution and Education Needs of Village Leaders